Type I PRMT inhibition protects against C9ORF72 arginine-rich dipeptide repeat toxicity
Alan S. Premasiri, Anna L. Gill, Fernando G. Vieira
The paper identifies Type I PRMT inhibitors as potential therapeutics for polyGR- and polyPR-related toxicity by showing ADMe of polyGR is critical for its pathogenesis.
Frontiers in Pharmacology · Sep 8, 2020Peer-reviewedNeuroscience